Literature DB >> 33864797

Outcomes of Extremely Premature Infants Comparing Patent Ductus Arteriosus Management Approaches.

Gabriel Altit1, Sahar Saeed2, Marc Beltempo3, Martine Claveau4, Anie Lapointe5, Olga Basso6.   

Abstract

OBJECTIVE: To evaluate the change in the proportion of deaths/bronchopulmonary dysplasia (BPD) among premature infants (<26 and 26-29 weeks) following a policy change to a strict non-intervention approach, compared with standard treatment. STUDY
DESIGN: We examined 1249 infants (341 <26 weeks) at two comparable sites. Site #1 (control) continued medical treatment/ligation, and site #2 (exposed) changed to a non-intervention policy in late 2013. Using the difference-in-differences approach, which accounts for time-invariant differences between sites and secular trends, we assessed changes in death or BPD separately among 26-29 weeks and <26 weeks in two epochs (epoch 1: 2011-2013; epoch 2: 2014-2017).
RESULTS: Baseline characteristics were similar across sites and epochs. Medical treatment/ligation use remained stable at site #1 but declined progressively to 0% at site #2, indicating adherence to policy. We saw no difference in death/BPD among babies born at 26-29 weeks (12%, 95%CI: -1 to 24%). However, incidence of death/BPD increased by 31% among <26 weeks [95% CI: 10 to 51%] in site #2, whereas there was no change in outcomes in site #1. The Score for Neonatal Acute Physiology-Version II, used as a control outcome, did not change in either site, suggesting that our findings were not due to changes in patients' severity.
CONCLUSION: Adherence to a strict conservative policy did not impact death or BPD among ≥26 weeks but was associated with a significant rise in infants born <26 weeks.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 33864797     DOI: 10.1016/j.jpeds.2021.04.014

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  5 in total

1.  Natural evolution of the patent ductus arteriosus in the extremely premature newborn and respiratory outcomes.

Authors:  Gabriela de Carvalho Nunes; Punnanee Wutthigate; Jessica Simoneau; Marc Beltempo; Guilherme Mendes Sant'Anna; Gabriel Altit
Journal:  J Perinatol       Date:  2021-11-23       Impact factor: 2.521

Review 2.  The role of furosemide and fluid management for a hemodynamically significant patent ductus arteriosus in premature infants.

Authors:  Sarah Dudley; Shawn Sen; Alison Hanson; Afif El Khuffash; Philip T Levy
Journal:  J Perinatol       Date:  2022-07-15       Impact factor: 3.225

3.  The biventricular contribution to chronic pulmonary hypertension of the extremely premature infant.

Authors:  Gabriela de Carvalho Nunes; Punnanee Wutthigate; Jessica Simoneau; Adrian Dancea; Marc Beltempo; Claudia Renaud; Gabriel Altit
Journal:  J Perinatol       Date:  2022-08-25       Impact factor: 3.225

4.  Impact of patent ductus arteriosus shunt size and duration on risk of death or severe respiratory morbidity in preterm infants born in China.

Authors:  Yingping Deng; Haiyan Zhang; Zhuoyu Zhao; Juan Du; Ruimiao Bai; Patrick J McNamara
Journal:  Eur J Pediatr       Date:  2022-07-15       Impact factor: 3.860

Review 5.  Patent Ductus Arteriosus: A Contemporary Perspective for the Pediatric and Adult Cardiac Care Provider.

Authors:  Carl H Backes; Kevin D Hill; Elaine L Shelton; Jonathan L Slaughter; Tamorah R Lewis; Dany E Weisz; May Ling Mah; Shazia Bhombal; Charles V Smith; Patrick J McNamara; William E Benitz; Vidu Garg
Journal:  J Am Heart Assoc       Date:  2022-09-03       Impact factor: 6.106

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.